Neoplasm Treatment Market Size

  • Report ID: 3898
  • Published Date: Jul 26, 2024
  • Report Format: PDF, PPT

Neoplasm Treatment Market Size

Neoplasm Treatment Market size was valued at USD 187.51 Billion in 2023 and is likely to exceed USD 670.67 Billion by the end of 2036, expanding at over 10.3% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of neoplasm treatment is evaluated at USD 204.89 Billion. The growth of the market can be attributed to the increasing number of peoples suffering from malignant tumors, followed by the rising number of cases across the globe.  According to the data by the World Health Organization (WHO), over 10 million people died due to cancer in 2020, up from 9.6 million in 2018. Moreover, there were 2.26 million new cases of breast cancer, 2.21 million cases of lung cancer, and 1.41 million cases of prostate cancer in 2020 itself.

Neoplasms can be cancerous or non-cancerous growths in different organs of the body. Neoplasm is not swelling as in case of tumors, and a new unwanted growth. The factors causing the non-cancerous neoplasm are often unknown, as it doesn’t spread to other parts of the body. On the other hand, there are few factors that are linked to the growth of the cancerous neoplasm such as rise in the exposure to skin or toxin chemical. For instance, as per the American Academy of Dermatology Association estimated, nearly one in five Americans develops skin cancer in their lifetime.


Global-Neoplasm-Treatment-Market-scope
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3898
  • Published Date: Jul 26, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of neoplasm treatment is evaluated at USD 204.89 Billion.

The neoplasm treatment market size was valued at USD 187.51 Billion in 2023 and is likely to exceed USD 670.67 Billion by the end of 2036, expanding at over 10.3% CAGR during the forecast period i.e., between 2024-2036. Surging change in genetic mutations, increasing geriatric population are the major factors driving the market growth.

North America is expected to dominate majority industry share by 2036, attributed to rising cases of cancer in the region.

Thermo Fisher Scientific Inc., Bayer AG, Merck & Co., Inc., Novartis AG, Abbott Laboratories, Exelixis, Inc., Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche, Amgen Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample